Vince Anzalone
Vice President, Investor Relations
Replay available
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) Q2 2025 earnings conference call, held 2025-05-12. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Chris Anzalone
President and Chief Executive Officer
Dr. Bruce Given
Interim Chief Medical Scientist
Ken Muskowski
Chief Financial Officer (Outgoing)
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Arrowhead Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.879 Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. 00:00:04.879 -- 00:00:10.629 Throughout today's recorded presentation, all participants will be in a listen-only mode. 00:00:10.629 -- 00:00:14.796 After the presentation, there will be an opportunity to ask questions. 00:00:14.796 -- 00:00:19.925 I will now hand the conference over to Vince Anzalone, Vice President 00:00:19.925 -- 00:00:25.170 of Investor Relations for Arrowhead. Please go ahead, Vince. 00:00:25.855 -- 00:00:29.728 Thank you. And good afternoon, everyone. Thank you for joining us today to discuss Arrowhead's 00:00:29.728 -- 00:00:34.693 results for its fiscal 2025 second quarter, ended March 31st, 2025. 00:00:34.693 -- 00:00:39.077 With us today from management, our president and CEO, Dr. 00:00:39.077 -- 00:00:41.780 Chris Anzalone, who will provide an overview. 00:00:41.780 -- 00:00:46.545 Dr. Bruce Given, interim chief medical scientist, who will provide an update on our cardiometabolic 00:00:46.545 -- 00:00:51.971 pipeline. Andy Davis, senior vice president and head of global cardiometabolic 00:00:51.971 -- 00:00:56.377 franchise, who will provide an update on commercialization activities. 00:00:56.377 -- 00:01:01.303 Dr. James Hamilton, Chief Medical Officer and Head of R&D, who will discuss our earlier 00:01:01.303 -- 00:01:06.409 stage development programs, and Ken Muskowski, our outgoing Chief Financial Officer who 00:01:06.409 -- 00:01:10.093 is retiring this week, who will give a review of the financials. 00:01:10.093 -- 00:01:15.119 We also welcome Dan Appel, our incoming CFO, who is also with us on the 00:01:15.119 -- 00:01:20.105 call today. Following management's prepared remarks, we will open the call to questions. 00:01:...